---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-013037"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:48:58.902452+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CervoMed: neflamapimod increases basal forebrain volume in DLB Phase 2b MRI analysis

## Summary
- At week 16, right BF volume increased 3.5% with neflamapimod vs -4.2% with placebo (p=0.028).
- Right BF to DMN functional connectivity improved 46% during 32-week extension (p=0.014).
- Improvement in functional connectivity correlated with CDR-SB reduction (p=0.027, r²=0.43).
- Company plans to start Phase 3 trial in DLB later this year, subject to financing.
- Data presented at 2026 AAN Annual Meeting by Amsterdam UMC; blinded analysis.

## SEC filing metadata
- accession: 0001437749-26-013037
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926013037/0001437749-26-013037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926013037/crvo20260422_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-013037
- JSON: https://secwatch.observer/filing/0001437749-26-013037.json
- Plain text: https://secwatch.observer/filing/0001437749-26-013037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.